Skip to main
TSHA
TSHA logo

TSHA Stock Forecast & Price Target

TSHA Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Taysha Gene Therapies Inc. has received regulatory approval for its pivotal TSHA-102 product in the REVEAL Part B clinical trial, effectively mitigating typical delays associated with gene therapies and enabling potential market share growth. The company continues to observe positive trends in patient outcomes across various clinical domains for Rett syndrome, suggesting promising efficacy of TSHA-102, especially at lower doses. Furthermore, ongoing discussions with regulatory agencies aim to define functional gain endpoints, reflecting Taysha's commitment to advancing its innovative gene therapy solutions and enhancing development flexibility with novel applications.

Bears say

Taysha Gene Therapies Inc. faces a challenging regulatory landscape that may lead to delays, impacting investor sentiment negatively, particularly if the development timeline extends longer than anticipated. There is an inherent risk associated with the company's AAV-based gene therapy platform, including potential safety concerns and manufacturing challenges that could further constrain forecasts. Additionally, the unique nature of gene therapies limits the patient pool over time, which may lead to reduced revenue opportunities as each indication becomes saturated.

TSHA has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Taysha Gene Therapies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Taysha Gene Therapies (TSHA) Forecast

Analysts have given TSHA a Buy based on their latest research and market trends.

According to 18 analysts, TSHA has a Buy consensus rating as of Aug 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Taysha Gene Therapies (TSHA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.